Indacaterol: A review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease

Drugs

Volumn 72, Issue 4, 2012, Pages 543-563

  McKeage, Kate ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Chronic obstructive pulmonary disease; Indacaterol; Pharmacoeconomics; Pharmacokinetics; Pharmacology

Indexed keywords

BREEZHALER; FORMOTEROL; HANDIHALER; INDACATEROL; KETOCONAZOLE; PLACEBO; RITONAVIR; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; VERAPAMIL;

AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; COUGHING; DISEASE SEVERITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EXERCISE TOLERANCE; HEADACHE; HEALTH STATUS; HEART INFARCTION; HUMAN; HYPERINFLATION; LUNG FUNCTION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUSCLE SPASM; NONHUMAN; REVIEW; RHINOPHARYNGITIS; SPIROMETRY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MAINTENANCE CHEMOTHERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84857283681     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208490-000000000-00000     Document Type: Review

References (52)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (revised 2011) [online]. Available from URL: http://www.goldcopd. org/uploads/users/files/GOLD-Report-2011Dec30.pdf [Accessed 2012 Feb 7]
2. European Medicines Agency. Onbrez Breezhaler (indacaterol) 150 mg inhalation powder, hard capsules: summary of product characteristics [online]. Available from URL: http://www. ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/001114/WC500053732.pdf [Accessed 2012 Jan 9]
3. Pavkov R, Mueller S, Fiebich K, et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010 Nov; 26 (11): 2527-33
4. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis 2011; 6: 353-63
5. Moen MD. Indacaterol: in chronic obstructive pulmonary disease. Drugs 2010 Dec 3; 70 (17): 2269-80
6. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1- hydroxy-ethyl]-8-hydroxy-1Hquinolin-2-one (indacaterol), a novel inhaled b2 adrenoceptor agonistwith a 24-h duration of action. J Pharmacol Exp Ther 2006 May; 317 (2): 762-70
7. Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting b2-agonist, on isolated human bronchi. Eur Respir J 2007 Mar; 29 (3): 575-81 (Pubitemid 46372108)
8. Baur F, Beattie D, Beer D, et al. The identification of indacaterol as an ultralong-acting inhaled b2-adrenoceptor agonist. J Med Chem 2010 May; 53 (9): 3675-84
9. Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009 Dec 8; 38 (5): 533-47
10. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008 Jul; 102 (7): 1033-44
11. Bauwens O, Ninane V, Van de Maele B, et al. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol. Curr Med Res Opin 2009 Feb; 25 (2): 463-70
12. Beier J, Beeh KM, Brookman L, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther 2009 Dec; 22 (6): 492-6
13. Laforce C, Aumann J, de Teresa Parreno L, et al. Sustained 24-hour efficacy of once daily indacaterol (300 mg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther 2011 Feb; 24 (1): 162-8
14. Balint B, Watz H, Amos C, et al. Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone. Int J Chron Obstruct Pulmon Dis 2010 Sep 7; 5: 311-8
15. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebocontrolled blinded comparison with tiotropium. Respir Res 2010 Oct 5; 11 (1): 135
16. Magnussen H, Verkindre C, Jack D, et al. Indacaterol oncedaily is equally effective dosed in the evening or morning in COPD. Respir Med 2010 Sep; 104 (12): 1869-76
17. O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Med 2011 Jul; 105 (7): 1030-6
18. Beeh KM, Wagner F, Khindri S, et al. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. COPD 2011 Oct; 8 (5): 340-5
19. Rossi A, Centanni S, Cerveri I, et al. Acute effects of indacaterol on lung hyperinflation in moderate COPD: a comparison with tiotropium. Respir Med 2012; 106 (1): 84-90
20. Puente-Maestu L, Villar F, de Miguel J, et al. Clinical relevance of constant power exercise duration changes in COPD. Eur Respir J 2009; 34: 340-5
21. Renard D, Looby M, Kramer B, et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res 2011; 12: 54
22. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo-and positive-controlled, parallel-group thorough QT study. BMC Pul Med 2011 May 26; 11 (31)
23. Worth H, Chung KF, Felser JM, et al. Cardio-and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011 Apr; 105 (4): 571-9
24. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulm Dis 2011 Sep; 6: 477-92
25. Perry S, Woessner R, Kaiser G, et al. Pharmacokinetics of indacaterol after single and multiple inhaled doses [abstract no. A4420]. Am J Respir Crit Care Med 2010; 181. Plus poster presented at the 106th International Conference of the American Thoracic Society; 2010 May 14-19; New Orleans (LA)
26. Hosoe M, Woessner R, Matsushima S, et al. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebocontrolled studies. Clin Drug Invest 2011; 31 (4): 247-55
27. Perry S, Goldsmith P, Vaidyanathan S, et al. No significant clinical drug-drug interaction potential with indacaterol [abstract no P3985 plus poster]. European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam
28. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011 May; 105 (5): 719-26
29. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new oncedaily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010 Jun; 65 (6): 473-9
30. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011 Feb; 37 (2): 273-9
31. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a doubleblind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11
32. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011 May; 38 (4): 797-803
33. Donohue JF, Fogarty C, Lö tvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2): 155-62
34. Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 mg in chronic obstructive pulmonary disease (COPD) patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology 2012 Feb; 17 (2): 379-89
35. To Y, Nishimura M, Fukuchi Y, et al. Long-term safety and tolerability of indacaterol versus salmeterol in Japanese COPD patients: a 52-week openlabeled study [abstract no. 240]. Respirology 2011; 16 Suppl. 2: 96
36. Mahler DA, D'Urzo A, Peckitt C, et al. Combining oncedaily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone [abstract no. A1591 plus poster]. 107th International Conference of the American Thoracic Society; 2011 May 13-18; Denver (CO)
37. Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010 Jun; 23 (3): 165-71
38. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting b2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011 Jul; 140 (1): 68-75
39. Bleecker ER, Siler T, Owen R, et al. Bronchodilator efficacy and safety of indacaterol 150 mg once daily in patients with COPD: an analysis of pooled data. Int J Chron Obstruct Pulm Dis 2011; 6: 431-8
40. Korn S, Kornmann O, Dunn L, et al. Efficacy of indacaterol is maintained in patients with moderate or less (GOLD III) and severe or worse (GOLD III-IV) COPD [abstract P860 plus poster]. European Respiratory Society Annual Congress; 2011 Sep 24-28; Amsterdam
41. Jones PW, Quirk FH, Bavesystock CM, et al. A selfcomplete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-7
42. Jones PW, Mahler DA, Gale R, et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med 2011 Jun; 105 (6): 892-9
43. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011 Nov; 105 (11): 1635-47
44. Oostenbrink JB, Rutten-van Molken MPH, Monz BU, et al. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8 (1): 32-46 (Pubitemid 40293639)
45. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-68
46. Novartis. Arcapt-Neohaler-(indacaterol inhalation powder) full prescribing information [online]. Available from URL: http://www.pharma.us. novartis.com/product/pi/pdf/arcapta.pdf [Accessed 2012 Jan 12]
47. Chowdhury BA, Seymour SM, Michele TM, et al. The risks and benefits of indacaterol: the FDA's review. N Engl J Med 2011; 365 (124): 2247-9
48. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23 (4): 257-67
49. Cope S, Capkun-Niggli G, Gale R, et al. Comparative efficacy of indacaterol 150 mg and 300 mg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis 2011; 6: 329-44
50. Schneider C, Bothner U, Jick SS, et al. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010; 25 (4): 253-60
51. Insulander P, Juhlin-Dannfelt A, Freyschuss U, et al. Electrophysiologic effects of salbutamol, a b2-selective agonist. J Cardiovasc Electrophysiol 2004; 15 (3): 316-22 (Pubitemid 38429447)
52. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011 Mar; 105 (3): 435-41